Media & Publications

PepGen Appoints Laurie Keating as Chair of Board of Directors

January 19, 2022

Keating brings strong experience as a life science executive and Board member BOSTON, January 19, 2022 – PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced that it has appointed Laurie Keating as Chair of the company’s Board of Directors. “We are very pleased that Laurie has agreed to join …

PepGen Appoints Laurie Keating as Chair of Board of Directors Read More »

PepGen Appoints Vice President of Program Management and Promotes Sonia Bracegirdle, Ph.D., to Senior Vice President, Strategy & Operations

December 7, 2021

PepGen Appoints Vice President of Program Management and Promotes Sonia Bracegirdle, Ph.D., to Senior Vice President, Strategy & Operations Dr. Bracegirdle to lead expanded PepGen Strategy and Operations team Isami J. Salcedo, experienced biotechnology operations and program management professional, joins as Vice President of Program Management BOSTON, Dec. 07, 2021 (GLOBE NEWSWIRE) — PepGen, Inc., …

PepGen Appoints Vice President of Program Management and Promotes Sonia Bracegirdle, Ph.D., to Senior Vice President, Strategy & Operations Read More »

PepGen Bolsters R&D Team with Appointment of Jaya Goyal, Ph.D., as Executive Vice President of Research and Preclinical Development

November 8, 2021

BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) — PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced the addition of Jaya Goyal, Ph.D., as Executive Vice President of Research and Preclinical Development. Dr. Goyal is an experienced scientific leader with an extensive background in biotech R&D, including in rare diseases. Most recently, …

PepGen Bolsters R&D Team with Appointment of Jaya Goyal, Ph.D., as Executive Vice President of Research and Preclinical Development Read More »

PepGen Appoints Noel Donnelly as Chief Financial Officer

October 28, 2021

New appointment represents continued expansion of PepGen’s leadership team in Boston following successful $112.5 million Series B financing BOSTON, Oct. 28, 2021 (GLOBE NEWSWIRE) — PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced that it has appointed Noel Donnelly as Chief Financial Officer. Mr. Donnelly is an experienced finance and …

PepGen Appoints Noel Donnelly as Chief Financial Officer Read More »

PepGen Welcomes Esteemed Neurologist Dr. John Day to Scientific Advisory Board

October 13, 2021

BOSTON, Oct. 13, 2021 (GLOBE NEWSWIRE) — PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced the appointment of neuromuscular neurologist John W. Day, M.D., Ph.D., to its Scientific Advisory Board. Dr. Day is a Professor of Neurology, Pediatrics (Genetics) and Pathology and Director of the Division of Neuromuscular Medicine at Stanford …

PepGen Welcomes Esteemed Neurologist Dr. John Day to Scientific Advisory Board Read More »

PepGen To Present Research on Enhanced Delivery Treatments for Neuromuscular Disease at Two Scientific Conferences in September

September 20, 2021

Presentations will highlight data supporting PepGen’s approach to developing treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1 BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) — PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular diseases, today announced that Chief Executive Officer James McArthur, Ph.D., will present on Pepgen’s Enhanced Delivery Oligonucleotide (EDO) therapeutic platform at two …

PepGen To Present Research on Enhanced Delivery Treatments for Neuromuscular Disease at Two Scientific Conferences in September Read More »

PepGen Announces New Additions to Leadership Team and Board of Directors

August 31, 2021

New appointments follow PepGen’s recent $112.5 million crossover financing to advance therapies for neuromuscular diseases PepGen is rapidly advancing lead programs in Duchenne muscular dystrophy and myotonic dystrophy type 1 to the clinic and growing its team in Boston, MA. BOSTON, Aug. 31, 2021 — PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular diseases, today …

PepGen Announces New Additions to Leadership Team and Board of Directors Read More »

PepGen Announces Closing of $112.5 Million Crossover Financing to Advance Transformative Therapies for Neuromuscular Diseases

August 5, 2021

Proceeds to support expansion and advancement of PepGen’s pipeline of Enhanced Delivery Oligonucleotide (EDO) therapies for neuromuscular and neurologic diseases   BOSTON, August 5, 2021 – PepGen, Inc., a company developing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced the closing of an oversubscribed $112.5 million crossover financing, led by a strong syndicate of …

PepGen Announces Closing of $112.5 Million Crossover Financing to Advance Transformative Therapies for Neuromuscular Diseases Read More »

PepGen Strengthens Leadership Team with SVP of Chemistry, Manufacturing & Controls and VP of Finance Appointments

June 7, 2021

– Niels Svenstrup, Ph.D., will serve as Senior Vice President of Chemistry, Manufacturing & Controls – David Pelissier, CPA, will serve as Vice President of Finance – New leaders will support PepGen in establishing its U.S. presence, building its financial strategy and advancing its pipeline BOSTON and OXFORD, United Kingdom, June 07, 2021 (GLOBE NEWSWIRE) …

PepGen Strengthens Leadership Team with SVP of Chemistry, Manufacturing & Controls and VP of Finance Appointments Read More »

PepGen to Present at Stifel’s 3rd Annual CNS Day

March 23, 2021

Boston, Mass. and Oxford, UK (March 23, 2021) – PepGen, Inc. a biotechnology company developing transformative therapies for individuals living with neuromuscular and neurologic diseases, today announced that Dr. James McArthur, CEO, will present at Stifel’s 3rd Annual CNS Day virtual conference. The presentation is scheduled for Wednesday, March 31, 2021 at 4:30 p.m. ET. …

PepGen to Present at Stifel’s 3rd Annual CNS Day Read More »

PepGen Appoints Laurie Keating as Chair of Board of Directors

Keating brings strong experience as a life science executive and Board member BOSTON, January 19, 2022 – PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced that it has appointed Laurie Keating as Chair of the company’s Board of Directors. “We are very pleased that …

Read More

PepGen Appoints Vice President of Program Management and Promotes Sonia Bracegirdle, Ph.D., to Senior Vice President, Strategy & Operations

PepGen Appoints Vice President of Program Management and Promotes Sonia Bracegirdle, Ph.D., to Senior Vice President, Strategy & Operations Dr. Bracegirdle to lead expanded PepGen Strategy and Operations team Isami J. Salcedo, experienced biotechnology operations and program management professional, joins as Vice President of Program Management BOSTON, Dec. 07, 2021 …

Read More

PepGen Bolsters R&D Team with Appointment of Jaya Goyal, Ph.D., as Executive Vice President of Research and Preclinical Development

BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) — PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced the addition of Jaya Goyal, Ph.D., as Executive Vice President of Research and Preclinical Development. Dr. Goyal is an experienced scientific leader with an extensive background in biotech R&D, including …

Read More

PepGen Appoints Noel Donnelly as Chief Financial Officer

New appointment represents continued expansion of PepGen’s leadership team in Boston following successful $112.5 million Series B financing BOSTON, Oct. 28, 2021 (GLOBE NEWSWIRE) — PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced that it has appointed Noel Donnelly as Chief Financial Officer. Mr. Donnelly …

Read More

PepGen Welcomes Esteemed Neurologist Dr. John Day to Scientific Advisory Board

BOSTON, Oct. 13, 2021 (GLOBE NEWSWIRE) — PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced the appointment of neuromuscular neurologist John W. Day, M.D., Ph.D., to its Scientific Advisory Board. Dr. Day is a Professor of Neurology, Pediatrics (Genetics) and Pathology and Director of the Division …

Read More

PepGen To Present Research on Enhanced Delivery Treatments for Neuromuscular Disease at Two Scientific Conferences in September

Presentations will highlight data supporting PepGen’s approach to developing treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1 BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) — PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular diseases, today announced that Chief Executive Officer James McArthur, Ph.D., will present on Pepgen’s Enhanced Delivery Oligonucleotide …

Read More

PepGen Announces New Additions to Leadership Team and Board of Directors

New appointments follow PepGen’s recent $112.5 million crossover financing to advance therapies for neuromuscular diseases PepGen is rapidly advancing lead programs in Duchenne muscular dystrophy and myotonic dystrophy type 1 to the clinic and growing its team in Boston, MA. BOSTON, Aug. 31, 2021 — PepGen, Inc., a company advancing next-generation …

Read More

PepGen Announces Closing of $112.5 Million Crossover Financing to Advance Transformative Therapies for Neuromuscular Diseases

Proceeds to support expansion and advancement of PepGen’s pipeline of Enhanced Delivery Oligonucleotide (EDO) therapies for neuromuscular and neurologic diseases   BOSTON, August 5, 2021 – PepGen, Inc., a company developing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced the closing of an oversubscribed $112.5 million crossover financing, led …

Read More

PepGen Strengthens Leadership Team with SVP of Chemistry, Manufacturing & Controls and VP of Finance Appointments

– Niels Svenstrup, Ph.D., will serve as Senior Vice President of Chemistry, Manufacturing & Controls – David Pelissier, CPA, will serve as Vice President of Finance – New leaders will support PepGen in establishing its U.S. presence, building its financial strategy and advancing its pipeline BOSTON and OXFORD, United Kingdom, …

Read More

PepGen to Present at Stifel’s 3rd Annual CNS Day

Boston, Mass. and Oxford, UK (March 23, 2021) – PepGen, Inc. a biotechnology company developing transformative therapies for individuals living with neuromuscular and neurologic diseases, today announced that Dr. James McArthur, CEO, will present at Stifel’s 3rd Annual CNS Day virtual conference. The presentation is scheduled for Wednesday, March 31, …

Read More